Skip to main content

Table 3 Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*

From: Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

A
Treatment Comparator Mean difference, ml
(95 % CrI)
Probability of non-inferiority
Margin (ml)
75 100 125
FF/VI 92/22 FP/SAL 250/50 −0.046 (−0.102–0.010) 84 % 97 % >99 %
FF/VI 92/22 BUD/FORM 320/9 −0.037 (−0.106–0.032) 86 % 96 % 99 %
FF/VI 184/22 FP/SAL 500/50 0.163 (0.058–0.269) >99 % >99 % >99 %
FF/VI 184/22 BUD/FORM 640/18 0.099 (−0.043–0.241) 99 % >99 % >99 %
B
Treatment Comparator Mean difference, units
(95 % CrI)
Probability of non-inferiority
Margin (units)
0.25 0.5
FF/VI 92/22 FP/SAL 250/50 93 (−43–230) >99 % >99 %
FF/VI 92/22 BUD/FORM 320/9 89 (−502–680) 93 % 95 %
  1. For studies requiring patients to be treated with ICS only at baseline
  2. *Other relevant ICS/LABA: FP/SAL 250/50 mcg and 500/50 mcg; BUD/FORM 320/9 mcg and 640/18 mcg
  3. a) change from baseline in FEV1. b) AQLQ Total score#
  4. Note: All stated doses are mcg
  5. # For reasons of model stability, only study length was included as a covariate in analysis of moderate/severe exacerbations data
  6. AQLQ Asthma quality of life questionnaire, BUD Budesonide, CrI Credible interval, FORM Formoterol, FEV 1 Forced expiratory volume in 1 s, FF Fluticasone furoate, FP Fluticasone propionate, SAL Salmeterol, VI Vilanterol